Clinical Trial

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

Name: Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer — clinical trial record (NCT07752550)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.

Trial Details

NCT Number	NCT07752550
Lead Sponsor	Harbin Medical University
Conditions	Triple-Negative Breast Cancer (TNBC)
Enrollment	120 participants
Start Date	2026-07-30
Primary Completion	2028-07-30 (estimated)
Study Completion	2029-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-07